Infographic | The leaders of the global hepatitis-C market
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
AbbVie’s new HCV drug is cheaper than Gilead’s Harvoni; Lilly’s experimental migraine drugs beats placebo; Fitbit to launch smartwatch
An unbranded campaign encouraging baby boomers to get tested for hepatitis C helped boost screening and diagnosis numbers, which in turn upped sales of its HCV therapies.
Samsung Bioepis launches Remicade biosimilar; WHO encourages uses of generic version of Sovaldi; nearly 20 million people with HIV on treatment
Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
A panel recommends the U.S. government license a hepatitis-C therapy; the FDA approves Roche MS drug; new eczema drug to cost $37,000 per year
Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
Gilead forms network to encourage access to hep.-C drugs; Dentsu CEO to resign following the suicide of a staffer; BI to divest animal-health products
The drugmaker’s new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.
The FDA to require black-box warnings for hep.-C drugs; AstraZeneca’s Brilinta fails to meet study goals; ICER says PD-1s are too pricey